Novartis International AG (NVS: Quote) showcased ongoing research at ASCO to help patients fight various cancers, including updated data in advanced breast cancer. These studies show key findings for Novartis compounds to address unmet treatment needs of patients with cancer and rare diseases.
Hervé Hoppenot, President, Novartis Oncology said, "Among the data we will share at this year's ASCO are results from our key products, Afinitor and Tasigna, which demonstrate the magnitude of benefit these treatments may provide for patients with some types of advanced breast cancer and chronic myeloid leukemia."
In addition, the company sees promising data from its early pipeline across multiple disease areas, including non-small cell lung cancer, multiple myeloma, NRAS-mutated melanoma and other solid tumors.
The updated results demonstrate median progression-free survival for everolimus plus exemestane was 7.8 months compared to 3.2 months with hormonal therapy alone by local investigator assessment and significantly reduced the risk of cancer progression by 55% versus exemestane alone.
Click here to receive FREE breaking news email alerts for Novartis AG and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org